PL2844672T3 - Ludzkie przeciwciała dla Fel d1 i sposoby ich stosowania - Google Patents

Ludzkie przeciwciała dla Fel d1 i sposoby ich stosowania

Info

Publication number
PL2844672T3
PL2844672T3 PL13721544T PL13721544T PL2844672T3 PL 2844672 T3 PL2844672 T3 PL 2844672T3 PL 13721544 T PL13721544 T PL 13721544T PL 13721544 T PL13721544 T PL 13721544T PL 2844672 T3 PL2844672 T3 PL 2844672T3
Authority
PL
Poland
Prior art keywords
fel
methods
human antibodies
antibodies
human
Prior art date
Application number
PL13721544T
Other languages
English (en)
Inventor
Jamie ORENGO
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2844672(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL2844672T3 publication Critical patent/PL2844672T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
PL13721544T 2012-05-03 2013-05-02 Ludzkie przeciwciała dla Fel d1 i sposoby ich stosowania PL2844672T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261642083P 2012-05-03 2012-05-03
US201261718044P 2012-10-24 2012-10-24
US201361783312P 2013-03-14 2013-03-14
PCT/US2013/039192 WO2013166236A1 (en) 2012-05-03 2013-05-02 Human antibodies to fel d1 and methods of use thereof
EP13721544.8A EP2844672B1 (en) 2012-05-03 2013-05-02 Human antibodies to fel d1 and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2844672T3 true PL2844672T3 (pl) 2020-08-10

Family

ID=48326501

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19218187T PL3660047T3 (pl) 2012-05-03 2013-05-02 Ludzkie przeciwciała przeciwko fel d1 i sposoby ich użycia
PL13721544T PL2844672T3 (pl) 2012-05-03 2013-05-02 Ludzkie przeciwciała dla Fel d1 i sposoby ich stosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19218187T PL3660047T3 (pl) 2012-05-03 2013-05-02 Ludzkie przeciwciała przeciwko fel d1 i sposoby ich użycia

Country Status (33)

Country Link
US (6) US9079948B2 (pl)
EP (4) EP2844672B1 (pl)
JP (2) JP6400569B2 (pl)
KR (1) KR102185516B1 (pl)
CN (2) CN110240651B (pl)
AR (1) AR090914A1 (pl)
AU (2) AU2013256251C1 (pl)
BR (2) BR122019023685B1 (pl)
CA (1) CA2871077C (pl)
CY (2) CY1124023T1 (pl)
DK (2) DK3978522T3 (pl)
ES (3) ES2780392T3 (pl)
FI (1) FI3978522T3 (pl)
HR (2) HRP20200652T1 (pl)
HU (2) HUE057062T2 (pl)
IL (1) IL235121B (pl)
IN (1) IN2014DN08767A (pl)
JO (1) JO3820B1 (pl)
LT (3) LT3660047T (pl)
MX (2) MX377634B (pl)
MY (3) MY181422A (pl)
NZ (2) NZ733480A (pl)
PL (2) PL3660047T3 (pl)
PT (3) PT3660047T (pl)
RS (2) RS60282B1 (pl)
RU (1) RU2658491C2 (pl)
SG (3) SG11201406748QA (pl)
SI (3) SI2844672T1 (pl)
SM (3) SMT202500396T1 (pl)
TW (2) TW201803901A (pl)
UY (1) UY34782A (pl)
WO (1) WO2013166236A1 (pl)
ZA (3) ZA201407302B (pl)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2015027154A2 (en) * 2013-08-23 2015-02-26 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3699198B1 (en) 2014-11-17 2025-03-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
CA2995003A1 (en) * 2015-09-08 2017-03-16 Universitat Zurich Compositions against cat allergy
CN109071665B (zh) 2016-04-18 2022-11-01 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
WO2018118713A1 (en) * 2016-12-22 2018-06-28 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
JP7112409B2 (ja) * 2017-01-24 2022-08-03 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 抗Ｆｅｌ Ｄ１抗体を含む組成物及びヒトのネコアレルギーの少なくとも１つの症状を減少させる方法
EP3967765A1 (en) 2017-07-06 2022-03-16 FrieslandCampina Nederland B.V. Cell culture process for making a glycoprotein
WO2019126123A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
AU2019215363A1 (en) 2018-01-31 2020-07-23 Regeneron Pharmaceuticals, Inc. System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
KR20200127979A (ko) 2018-02-28 2020-11-11 리제너론 파마슈티칼스 인코포레이티드 바이러스 오염물질을 확인하기 위한 시스템 및 방법
EP4317959A3 (en) 2018-03-19 2024-03-27 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
EP3794026A4 (en) 2018-05-18 2022-06-22 Chan Zuckerberg Biohub, Inc. METHODS FOR ISOLATION OF ALLERGEN-SPECIFIC ANTIBODIES FROM HUMANS AND THEIR USES
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
BR112020026348A2 (pt) 2018-08-30 2021-03-30 Regeneron Pharmaceuticals, Inc. Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
KR20210114927A (ko) 2019-01-16 2021-09-24 리제너론 파마슈티칼스 인코포레이티드 이황화 결합을 특징 짓는 방법
MX2021013519A (es) 2019-05-13 2021-12-10 Regeneron Pharma Ensayos de union de ligandos competitivos mejorados.
CN114667450B (zh) 2019-09-24 2025-05-02 里珍纳龙药品有限公司 用于色谱介质的使用和再生的系统及方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
EP4354145B1 (en) 2020-01-21 2025-09-17 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
EP4204449A1 (en) 2020-08-26 2023-07-05 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
KR20230113280A (ko) 2020-11-25 2023-07-28 리제너론 파마슈티칼스 인코포레이티드 비수성 멤브레인 유화법을 사용한 지속 방출 제형
CN116710124A (zh) 2020-12-17 2023-09-05 瑞泽恩制药公司 包封蛋白质的微凝胶的制造
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
AR125585A1 (es) 2021-03-03 2023-08-02 Regeneron Pharma Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
EP4305190A4 (en) 2021-03-11 2025-03-26 Iggenix, Inc. METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION
MX2023010794A (es) 2021-03-26 2023-10-25 Regeneron Pharma Metodos y sistemas para el desarrollo de protocolos de mezcla.
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
JP2024531800A (ja) 2021-09-20 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体の不均一性を制御する方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
CA3236367A1 (en) 2021-10-26 2023-05-04 Michelle Lafond Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
CN114113278B (zh) * 2021-11-24 2024-08-02 中国计量科学研究院 一种基于质谱的体外诊断试剂抗体的表位定位方法
CN118660719A (zh) * 2021-12-08 2024-09-17 艾吉尼克斯公司 用于过敏症疗法的组合
JP2025508233A (ja) 2022-03-18 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ポリペプチド変異体を分析するための方法およびシステム
EP4544081A1 (en) 2022-06-23 2025-04-30 Regeneron Pharmaceuticals, Inc. Methods of identifying and evaluating cat allergy gene signatures in a subject by determining a stratified score based on gene expression
WO2024130048A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
TW202445126A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 基於質譜法之體內共表現抗體之表徵
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
AU2024229494A1 (en) 2023-03-01 2025-09-11 Regeneron Pharmaceuticals, Inc. Anti-fel d1 antibody formulations
WO2024200854A1 (en) 2023-03-31 2024-10-03 Alk-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
CN117004650B (zh) * 2023-06-25 2024-05-14 山东立菲生物产业有限公司 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117069865B (zh) * 2023-10-12 2024-03-01 中国农业科学院饲料研究所 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
WO2025096932A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
CN117964767B (zh) * 2024-03-29 2024-08-06 北京恩泽康泰生物科技有限公司 抗rage抗体、细胞外囊泡及其制备方法和应用
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512283A (en) 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
WO1993013772A1 (en) * 1992-01-21 1993-07-22 Immulogic Pharmaceutical Corporation Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
AU5958494A (en) 1992-12-21 1994-07-19 Tanox Biosystems, Inc. Allergen-specific iga monoclonal antibodies and related products for allergy treatment
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ES2424229T3 (es) * 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
GB0513878D0 (en) * 2005-07-06 2005-08-10 Mars Inc Cat allergen
WO2007065633A1 (en) * 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
WO2007113633A2 (en) * 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1921142A1 (en) * 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
ES2667863T3 (es) * 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
JP6071165B2 (ja) * 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US8454953B2 (en) * 2007-07-09 2013-06-04 Nestec Sa Methods for reducing allergies caused by environmental allergens
US7988967B2 (en) * 2007-08-10 2011-08-02 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
WO2015027154A2 (en) 2013-08-23 2015-02-26 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2018118713A1 (en) 2016-12-22 2018-06-28 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies

Also Published As

Publication number Publication date
JO3820B1 (ar) 2021-01-31
SI3660047T1 (sl) 2021-12-31
HK1202123A1 (en) 2015-09-18
RU2658491C2 (ru) 2018-06-21
MX377634B (es) 2025-03-10
US20160376358A1 (en) 2016-12-29
HUE057062T2 (hu) 2022-04-28
MY195564A (en) 2023-02-02
US20180305446A1 (en) 2018-10-25
AU2013256251B2 (en) 2018-04-12
DK3978522T3 (da) 2025-10-27
US20130295097A1 (en) 2013-11-07
TWI644921B (zh) 2018-12-21
US9079948B2 (en) 2015-07-14
EP3660047B1 (en) 2021-10-13
KR102185516B1 (ko) 2020-12-02
RU2014148502A (ru) 2016-06-27
ES2780392T3 (es) 2020-08-25
US20170210790A1 (en) 2017-07-27
JP6603269B2 (ja) 2019-11-06
KR20150005666A (ko) 2015-01-14
CY1124819T1 (el) 2022-11-25
PT3660047T (pt) 2021-11-30
AU2018203087A1 (en) 2018-05-24
CN104411719B (zh) 2019-05-14
EP4653056A2 (en) 2025-11-26
FI3978522T3 (fi) 2025-11-13
IN2014DN08767A (pl) 2015-05-22
AU2013256251A1 (en) 2014-11-06
JP6400569B2 (ja) 2018-10-03
RS62636B1 (sr) 2021-12-31
US20220025029A1 (en) 2022-01-27
HRP20211932T1 (hr) 2022-03-18
CN104411719A (zh) 2015-03-11
SMT202500396T1 (it) 2025-11-10
CN110240651A (zh) 2019-09-17
PL3660047T3 (pl) 2022-02-14
CA2871077C (en) 2021-08-17
MX2020003864A (es) 2020-08-13
TW201803901A (zh) 2018-02-01
EP2844672A1 (en) 2015-03-11
EP3978522B1 (en) 2025-10-01
DK2844672T3 (da) 2020-04-20
MY181422A (en) 2020-12-21
AR090914A1 (es) 2014-12-17
SMT202200014T1 (it) 2022-03-21
NZ701124A (en) 2017-07-28
ZA202005273B (en) 2023-11-29
NZ733480A (en) 2019-03-29
AU2013256251C1 (en) 2018-08-23
LT3978522T (lt) 2025-11-25
AU2018203087B2 (en) 2020-03-12
SI2844672T1 (sl) 2020-07-31
CY1124023T1 (el) 2022-03-24
PT2844672T (pt) 2020-04-30
US11174305B2 (en) 2021-11-16
HRP20200652T1 (hr) 2020-07-10
ES2898372T3 (es) 2022-03-07
BR122019023685B1 (pt) 2023-01-17
US20150299303A1 (en) 2015-10-22
IL235121A0 (en) 2014-12-31
WO2013166236A1 (en) 2013-11-07
SG10202102919XA (en) 2021-05-28
US12252530B2 (en) 2025-03-18
MX2014013371A (es) 2015-02-05
MY164101A (en) 2017-11-30
EP3660047A1 (en) 2020-06-03
CN110240651B (zh) 2024-03-08
TW201406779A (zh) 2014-02-16
UY34782A (es) 2013-11-29
CA2871077A1 (en) 2013-11-07
ES3049982T3 (en) 2025-12-19
ZA201407302B (en) 2021-08-25
JP2015523962A (ja) 2015-08-20
EP3978522A2 (en) 2022-04-06
RS60282B1 (sr) 2020-06-30
US9475869B2 (en) 2016-10-25
EP3978522A3 (en) 2022-07-06
EP2844672B1 (en) 2020-02-12
SG10201608378UA (en) 2016-11-29
HUE049440T2 (hu) 2020-09-28
LT2844672T (lt) 2020-04-10
SG11201406748QA (en) 2014-11-27
IL235121B (en) 2019-06-30
US10047152B2 (en) 2018-08-14
BR112014026852B1 (pt) 2023-01-03
LT3660047T (lt) 2021-11-10
BR112014026852A2 (pt) 2017-07-18
JP2017153491A (ja) 2017-09-07
ZA202202846B (en) 2023-11-29
SMT202000241T1 (it) 2020-07-08
AU2018203087B9 (en) 2020-03-26
US10047153B2 (en) 2018-08-14
PT3978522T (pt) 2025-10-17
SI3978522T1 (sl) 2025-11-28

Similar Documents

Publication Publication Date Title
ES3049982T3 (en) Human antibodies to fel d1 and methods of use thereof
IL236738A0 (en) Human antibodies to gfra3 and methods of using them
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
LT2806892T (lt) Kombinuota terapija, panaudojant antikūnus ir endoglikozidazes
ZA201408236B (en) Anti-ly6e antibodies and immunoconjugates and methods of use
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
GB201223276D0 (en) Antibodies and methods of producing same
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
EP2825199A4 (en) ANTIBODIES AGAINST HUMAN AUTOTAXIN AND METHODS OF USE